Table 4.
Comparison of BCR-ABL1 HTs at different time points in patients treated with IM and stratified according to the achieved molecular responses.
| Clinical context at time of BCR-ABL1 decrease | No of samples analyzed | HT (range) | Median BCR-ABL1/ABL1IS before the decrease (range) | Median BCR-ABL1/ABL1IS after the decrease (range) | p-value |
|---|---|---|---|---|---|
| IM w/o MR3.0 by 6 months | 50 | 39.00 (14.9–142.6) | 1.760 (0.210–9.540) | 0.267 (0.115–0.989) | p = 0.002 |
| IM with MR3.0 by 6 months | 40 | 21.90 (13.0–131.6) | 0.524 (0.109–5.364) | 0.033 (0.001–0.098) | |
| IM w/o MR3.0 by 12 months | 22 | 97.65 (26.4–354.3) | 1.320 (0.93–9.60) | 0.621 (0.188–1.030) | p <0.001 |
| IM with MR3.0 by 12 months | 89 | 30.60 (7.8–156.1) | 0.263 (0.112–4.244) | 0.040 (0.001–0.098) | |
| IM w/o MR4.0 by 18 months | 39 | 76.70 (15.1–179.9) | 0.100 (0.021–1.002) | 0.038 (0.011–0.099) | p = 0.0099 |
| IM with MR4.0 by 18 months | 65 | 50.10 (15.5–192.2) | 0.011 (0.000–0.678) | 0.003 (0.000–0.033) |